Homepage Top Section1

In January 2018, the company announced that crizanlizumab was granted breakthrough therapy designation by the FDA. Novartis’ application for the investigational drug is backed by results from a

Last month, a phase 3 trial called CASPIAN met its primary endpoint with Imfinzi by delivering a statistically-significant and clinically-meaningful improvement in overall survival for patients suffering from

An investigational monoclonal antibody, isatuximab, has been designed to target a specific epitope on the CD38 receptor of a plasma cell. The drug has been designed to activate

ViiV Healthcare said that its team will work with clinical staff at different sites across the US to conduct one-year CUSTOMIZE trial (cabotegravir plus rilpivirine in the US

Close to 8,000 participants are being enrolled by BiondVax for the second cohort for the late-stage trial of M-001 in 85 sites across seven countries in eastern Europe.

Dovato is a new once-daily, single-pill and two-drug regimen approved for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at least

The sale of Xiidra has also provided an option to Takeda to receive up to an additional $1.9bn (£1.5bn) in potential milestone payments from Novartis. Takeda intends to

Pfizer said that Zirabev has been approved to treat five types of cancer, including metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer

The NMOSD is a rare and severe autoimmune disease, which attacks the central nervous system without warning. Also referred as relapses, the attacks may result in progressive and